Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Packer

Showing results (81-90 of 326) with videos related to

Pageof 33
Sort By:
American Heart Journal|January 1, 1987
Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failureP D Kessler, M Packer
The New England Journal of Medicine|January 5, 1995
The use of placebo controlsE M Gilbert, M Packer
The American Journal of Cardiology|October 1, 1982
Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspectiveM Packer, W H Frishman
Journal of the American College of Cardiology|October 1, 1993
Role of surrogate end points in the evaluation of drugs for heart failureR J Lipicky, M Packer
Survey of Ophthalmology|March 1, 1992
Ophthalmology's botanical heritageM Packer, J D Brandt
The American Journal of Cardiology|February 1, 1986
Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failureM Packer, W H Lee
American Heart Journal|September 1, 1989
Deleterious hemodynamic effects of lidocaine in severe congestive heart failureS S Gottlieb, M Packer
Circulation|May 1, 1987
Survival in congestive heart failure during treatment with drugs with positive inotropic actionsM Packer, C V Leier
The American Journal of Cardiology|September 10, 1999
Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failureM Packer, A B Miller
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 16, 2011
Dense, unspecific connectivity of neocortical parvalbumin-positive interneurons: a canonical microcircuit for inhibition?Adam M Packer, Rafael Yuste
Pageof 33

Showing results (81-90 of 326) with videos related to

Sort By:
Pageof 33
American Heart Journal|January 1, 1987
Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failureP D Kessler, M Packer
The New England Journal of Medicine|January 5, 1995
The use of placebo controlsE M Gilbert, M Packer
The American Journal of Cardiology|October 1, 1982
Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspectiveM Packer, W H Frishman
Journal of the American College of Cardiology|October 1, 1993
Role of surrogate end points in the evaluation of drugs for heart failureR J Lipicky, M Packer
Survey of Ophthalmology|March 1, 1992
Ophthalmology's botanical heritageM Packer, J D Brandt
The American Journal of Cardiology|February 1, 1986
Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failureM Packer, W H Lee
American Heart Journal|September 1, 1989
Deleterious hemodynamic effects of lidocaine in severe congestive heart failureS S Gottlieb, M Packer
Circulation|May 1, 1987
Survival in congestive heart failure during treatment with drugs with positive inotropic actionsM Packer, C V Leier
The American Journal of Cardiology|September 10, 1999
Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failureM Packer, A B Miller
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 16, 2011
Dense, unspecific connectivity of neocortical parvalbumin-positive interneurons: a canonical microcircuit for inhibition?Adam M Packer, Rafael Yuste
Pageof 33